Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26251-26260 Newer>

The Motley Fool September 24, 2007 Rich Duprey	Lerach's Punishment Worse Than None at All William Lerach makes a plea agreement in his fraud case stemming from bogus class-action lawsuits. Investors, take note how this may have affected you.
The Motley Fool September 24, 2007 Amanda B. Kish	Fear Is Not Your Friend Fear can be a very useful emotion. But when it comes to investing and retirement planning, more often than not, fear works against us.
The Motley Fool September 24, 2007 Ryan Fuhrmann	Fool on the Street: Wal-Mart's Stateside Stall Big-box retailing behemoth Wal-Mart had a rough second quarter. Its struggles are nothing new; growth has been slowing at Wal-Mart ever since 2000.
The Motley Fool September 24, 2007 Billy Fisher	A Fountain of Youth? A study sponsored by Sirtris Pharmaceutical shows potential for the fight against aging. Investors, take note.
The Motley Fool September 24, 2007 Selena Maranjian	Turning a Drip Into a Gush Increasingly, you can have your dividends reinvested without having to set up Drip accounts, because many brokerages are now offering dividend reinvestment.
The Motley Fool September 24, 2007 Billy Fisher	Getting It Done at Meridian Bioscience Impressive earnings growth and disciplined spending continue to propel this small cap up and up. Investors, take note.
The Motley Fool September 24, 2007 Ryan Fuhrmann	Nike's Favorable Global Footprint Revenue increased in every region this quarter for Nike; and strong international growth easily offset anemic trends in the United States.
The Motley Fool September 24, 2007 Rick Aristotle Munarriz	A "Halo" to Light Up the Night Halo 3 is finally released. Xbox players have been waiting nearly three years for the third installment in Microsoft's galactic shoot-'em-up series.
The Motley Fool September 24, 2007 Rick Aristotle Munarriz	Is Wendy's Even Trying? Wendy's introduces their new breakfast menu, but a little more originality may be needed for the fast-food restaurant to compete in the crowded early-morning market.
The Motley Fool September 24, 2007 Jack Uldrich	Nanotech Is in the Genes The FDA's stamp of approval on a genetic test that will help patients better understand how they will metabolize anti-blood clot medication gives Nanosphere extra allure. Investors should take note.
<Older 26251-26260 Newer> Return to current articles.